# Progress Note 03 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Sun Yat-sen (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ET016-SYN-TD
- Date: 1924-06-01
- Fictional facility: St. Posthumous Health Center
- Fictional author: Wen-Li Huang, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Staging laparoscopy result, tumor board recommendation, and first cycle of treatment. **S**

## History of present illness

Mr. Sun returns two weeks after the consultation and five days after the staging laparoscopy. At laparoscopy the surgeon found several small nodules on the lining of the abdomen and the omentum, and their biopsy shows adenocarcinoma of the same type. The tumor board met two days later and advised against an operation and for chemoimmunotherapy. He has recovered from the laparoscopy; the port and the small wounds are healing. The ache under his ribs is unchanged at 2 of 10. He said he had expected this, as a physician, but found it hard to hear. He has slept poorly for several nights. He wants to start treatment today if he is fit for it and asked how long treatment might keep him working. **S**

| Element | Detail |
|---|---|
| Staging laparoscopy | Peritoneal and omental nodules; biopsy adenocarcinoma |
| Tumor board | Not resectable; first-line chemoimmunotherapy advised |
| Recovery | Wounds and port healing |
| Mood and sleep | Finds the news hard; sleeping poorly |
| His question | How long treatment may keep him working |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Tired; weight 60.0 kg; no fever |
| Gastrointestinal | Positive | Ache under the right ribs 2 of 10; no jaundice or vomiting |
| Psychiatric | Positive | Low at times and sleeping poorly since the result; no thoughts of self-harm |
| Integumentary | Negative | Port and laparoscopy wounds healing without redness |

4 systems reviewed. **S**

## Current medications

- Acetaminophen 500 mg oral tablet, two tablets by mouth every 8 hours as needed for right upper abdominal ache; no more than 3,000 mg a day **S**
- Gemcitabine 1,000 mg/m2 (1,660 mg) intravenous infusion on days 1 and 8 of each 21-day cycle **S**
- Cisplatin 25 mg/m2 (41 mg) intravenous infusion on days 1 and 8 of each 21-day cycle **S**
- Durvalumab 1,500 mg intravenous infusion on day 1 of each 21-day cycle **S**
- Ondansetron 8 mg oral tablet, one tablet by mouth every 8 hours as needed for nausea **S**

## Allergies

- No known allergy **S**

## Objective

BP 126/80 mmHg; pulse 84 bpm; respirations 16/min; temperature 36.7 °C; oxygen saturation 98% on room air; weight 60 kg; BMI 22 kg/m². All vital signs are synthetic.

White cells: 7.4 10*3/uL; Neutrophils: 4.9 10*3/uL; Hemoglobin: 12.2 g/dL (low); Platelets: 318 10*3/uL; Sodium: 137 mmol/L; Potassium: 4.3 mmol/L; Creatinine: 0.84 mg/dL; eGFR: 102 mL/min/1.73 m²; Magnesium: 2 mg/dL; Albumin: 3.4 g/dL (low); Total bilirubin: 0.8 mg/dL; Alkaline phosphatase: 236 U/L (high); AST: 52 U/L (high); ALT: 44 U/L; TSH: 1.9 mIU/L; CA 19-9: 498 U/mL (high); PHQ-9: 6; ECOG performance status: 1. All results are synthetic.

## Change since baseline

- White cells: 7.9 10*3/uL at baseline, 7.4 10*3/uL at this visit **S**
- Hemoglobin: 12.6 g/dL (low) at baseline, 12.2 g/dL (low) at this visit **S**
- Platelets: 342 10*3/uL at baseline, 318 10*3/uL at this visit **S**
- Sodium: 137 mmol/L at baseline, 137 mmol/L at this visit **S**
- Potassium: 4.2 mmol/L at baseline, 4.3 mmol/L at this visit **S**
- Creatinine: 0.86 mg/dL at baseline, 0.84 mg/dL at this visit **S**
- eGFR: 101 mL/min/1.73 m² at baseline, 102 mL/min/1.73 m² at this visit **S**
- Albumin: 3.4 g/dL (low) at baseline, 3.4 g/dL (low) at this visit **S**
- Total bilirubin: 0.9 mg/dL at baseline, 0.8 mg/dL at this visit **S**
- Alkaline phosphatase: 212 U/L (high) at baseline, 236 U/L (high) at this visit **S**
- AST: 48 U/L (high) at baseline, 52 U/L (high) at this visit **S**
- ALT: 41 U/L at baseline, 44 U/L at this visit **S**
- CA 19-9: 412 U/mL (high) at baseline, 498 U/mL (high) at this visit **S**
- ECOG performance status: 1 at baseline, 1 at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Thin, composed; blood pressure 126/80, pulse 84; weight 60.0 kg; no jaundice |
| Abdomen | Healing laparoscopy wounds; mass 4 cm below the right costal margin, unchanged; no ascites |
| Chest wall | Port site clean and dry |
| Ears, nose, mouth, and throat | Hears a whispered voice in both ears |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Peritoneal metastases from gallbladder adenocarcinoma** (C78.6). Peritoneal metastases confirmed by biopsy: stage IVB (any T, any N, M1). Not resectable; treatment aims to control the cancer, relieve symptoms and lengthen life, not to cure. **S**
   - Systemic therapy as below.
   - Restaging CT after three cycles.
2. **Gallbladder adenocarcinoma, stage IVB** (C23). ECOG 1, Child-Pugh A6, bilirubin 0.8 mg/dL, creatinine 0.84 mg/dL (estimated creatinine clearance about 80 mL/min), neutrophils 4.9 x10^3/uL and platelets 318 x10^3/uL: fit for gemcitabine, cisplatin and durvalumab, the first-line regimen Dr. Choi and the tumor board recommend. Baseline TSH 1.9 and CA 19-9 498 U/mL. Genomic profiling is pending. He chose to start today. **S**
   - Cycle 1 day 1 today: gemcitabine 1,000 mg/m2 and cisplatin 25 mg/m2 on days 1 and 8 with durvalumab 1,500 mg on day 1, every 21 days, for up to 8 cycles, then durvalumab every 4 weeks.
   - Ondansetron at home for nausea.
   - Teaching on fever, infection and immune-related side effects; oncology line number given.
   - Restaging CT after three cycles.
3. **Resolved hepatitis B infection** (Z86.19). HBV DNA undetectable before treatment. **S**
   - HBV DNA and ALT in about 2 to 3 months.
4. **Coping with a new diagnosis of advanced cancer**. PHQ-9 6 (mild), with low mood and poor sleep since the result and no thoughts of self-harm; an expected reaction to grave news. Specialist palliative care starts now alongside treatment. **S**
   - First palliative care visit next week.
   - Sleep advice; review the PHQ-9 at the next visit.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Imaging | Staging laparoscopy | Before resection of gallbladder cancer | Completed today | Peritoneal and omental nodules; biopsy adenocarcinoma: M1 |
| Referral | Multidisciplinary tumor board | Before treatment, and when the stage changes | Completed today | Not resectable; gemcitabine, cisplatin and durvalumab advised |
| Imaging | CT of the chest, abdomen and pelvis | At staging, then every 2 to 3 months on treatment | Due | Baseline from staging; restaging after three cycles |
| Laboratory | CA 19-9 (and CEA when raised) | At diagnosis, then with each cycle or restaging | Completed today | CA 19-9 498 U/mL at baseline |
| Laboratory | Blood count with neutrophils | Before every dose (days 1 and 8) | Completed today | White cells 7.4, neutrophils 4.9, hemoglobin 12.2 g/dL, platelets 318 |
| Laboratory | Creatinine and eGFR | Before every dose (days 1 and 8) | Completed today | Creatinine 0.84 mg/dL, eGFR 102; adequate for cisplatin |
| Laboratory | Magnesium and potassium | Before every dose (days 1 and 8) | Completed today | Magnesium 2.0 mg/dL, potassium 4.3 mmol/L, sodium 137 mmol/L |
| Laboratory | Liver tests (bilirubin, alkaline phosphatase, AST, ALT, albumin) | Before every dose (days 1 and 8) | Completed today | Bilirubin 0.8 mg/dL, alkaline phosphatase 236, AST 52, ALT 44 U/L, albumin 3.4 g/dL |
| Laboratory | TSH | Baseline, then every 4 to 6 weeks on durvalumab | Completed today | 1.9 mIU/L at baseline |
| Laboratory | Glucose | Baseline, then with each pre-dose chemistry panel on durvalumab | Deferred | Missed: today's pre-treatment panel was ordered as a renal panel with magnesium and did not include glucose. Glucose was 98 mg/dL at intake and he has no thirst or excess urination, so no harm is apparent. Corrective action: glucose added to the standing pre-dose order from the next draw |
| Laboratory | HBV DNA and ALT (resolved hepatitis B) | Every 3 months during treatment and for 6 to 12 months after | Up to date | HBV DNA undetectable before treatment; ALT 44 U/L today (liver tests above); next in 2 to 3 months |
| Examination | Hearing (cisplatin) | Baseline before cisplatin, then by symptoms each cycle | Deferred | Missed: no baseline audiogram before the first cisplatin dose; whispered-voice test normal today and no hearing symptoms. The lower 25 mg/m2 dose carries less risk; corrective action is to ask about hearing at each cycle and obtain an audiogram for any change |
| Survey | ECOG performance status | Every visit | Completed today | ECOG 1 |
| Examination | Weight and nutrition | Every visit | Completed today | 60.0 kg; dietitian advice followed |
| Survey | Pain | Every visit | Completed today | 2 of 10 on acetaminophen |
| Survey | Distress and depression (PHQ-9) | At diagnosis and at each change in treatment | Completed today | PHQ-9 6, mild; no thoughts of self-harm |
| Laboratory | Comprehensive genomic profiling of tumor tissue | At diagnosis of advanced disease | Ordered | Pending |
| Referral | Specialist palliative care | From the diagnosis of advanced cancer | Referred | First visit next week |
| Medication safety | Immune-related side effects (diarrhea, rash, cough or breathlessness, fatigue, endocrine symptoms) | Teaching before the first dose, then every visit | Completed today | Taught today with written information |

## Goal progress

- Tissue diagnosis and complete staging within four weeks of the first visit. Outcome by 1924-06-01: Biopsy diagnosis in nine days and staging complete by laparoscopy in about three and a half weeks. **S**
- Right upper abdominal pain at 3 of 10 or less, with full days of work possible (ECOG 0 to 1). In progress; target 1924-10-26. **S**
- Weight held within 2 kg of the weight at the start of treatment. In progress; target 1924-10-26. **S**
- Goals of care and a health care agent documented, and revisited as treatment changes. In progress; target 1924-09-21. **S**
- Complete first-line chemoimmunotherapy without grade 3 or higher toxicity. In progress; target 1924-10-26. **S**

## Medication changes

- Started: Gemcitabine 1,000 mg/m2 (1,660 mg) intravenous infusion on days 1 and 8 of each 21-day cycle **S**
- Started: Cisplatin 25 mg/m2 (41 mg) intravenous infusion on days 1 and 8 of each 21-day cycle **S**
- Started: Durvalumab 1,500 mg intravenous infusion on day 1 of each 21-day cycle **S**
- Started: Ondansetron 8 mg oral tablet, one tablet by mouth every 8 hours as needed for nausea **S**

## Guideline basis

- NCCN Clinical Practice Guidelines in Oncology: Biliary Tract Cancers (2026), National Comprehensive Cancer Network
- Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer (TOPAZ-1) (2022), NEJM Evidence
- Hepatitis B Virus Screening and Management for Patients With Cancer Prior to Therapy: ASCO Provisional Clinical Opinion Update (2020), American Society of Clinical Oncology (Journal of Clinical Oncology)
- Integration of Palliative Care Into Standard Oncology Care: American Society of Clinical Oncology Clinical Practice Guideline Update (2017), American Society of Clinical Oncology (Journal of Clinical Oncology)
- Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update (2021), American Society of Clinical Oncology (Journal of Clinical Oncology)

## Follow-up

- Cycle 1 day 8 next week; palliative care next week. Visit before cycle 4 with a restaging CT. **S**
- Next scheduled visit 1924-08-03: before cycle 4: restaging CT, tumor marker, toxicity review, hepatitis B monitoring, and genomic profiling result. **S**
